Spots Global Cancer Trial Database for adenocarcinoma of the gastroesophageal junction
Every month we try and update this database with for adenocarcinoma of the gastroesophageal junction cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer | NCT02485834 | Adenocarcinoma ... Gastric Adenoca... Gastric Cancer | FDG-PET surgery 5-FU capecitabine docetaxel Irinotecan 3D-CRT IMRT | 18 Years - | Alliance for Clinical Trials in Oncology | |
| A Survivorship Care Plan for Gynaecological Cancer Patients | NCT01582906 | Adenocarcinoma ... Cervical Cancer Endometrial Can... Esophageal Canc... Fallopian Tube ... Gastric Cancer Ovarian Cancer Sarcoma Vaginal Cancer Vulvar Cancer | 18 Years - 60 Years | Royal Marsden NHS Foundation Trust | ||
| Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer | NCT01231399 | Adenocarcinoma ... Adenocarcinoma ... Diffuse Adenoca... Intestinal Aden... Mixed Adenocarc... Recurrent Esoph... Recurrent Gastr... Stage IV Esopha... Stage IV Gastri... | fluorouracil leucovorin calc... oxaliplatin everolimus laboratory biom... immunohistochem... microarray anal... | 19 Years - | City of Hope Medical Center | |
| Gefitinib in Treating Patients With Esophageal Cancer That is Progressing After Chemotherapy | NCT01243398 | Adenocarcinoma ... Esophageal Canc... | quality-of-life... | 18 Years - | University of Oxford | |
| 64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer | NCT01939275 | Adenocarcinoma ... Diffuse Adenoca... Intestinal Aden... Mixed Adenocarc... Recurrent Gastr... Stage IA Gastri... Stage IB Gastri... Stage IIA Gastr... Stage IIB Gastr... Stage IIIA Gast... Stage IIIB Gast... Stage IIIC Gast... Stage IV Gastri... | copper Cu 64-DO... positron emissi... laboratory biom... Computed Tomogr... | 18 Years - | City of Hope Medical Center | |
| Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery | NCT01107639 | Adenocarcinoma ... Esophageal Canc... | cetuximab cisplatin docetaxel adjuvant therap... neoadjuvant the... | 18 Years - 75 Years | Swiss Group for Clinical Cancer Research | |
| Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction | NCT00938470 | Adenocarcinoma ... Esophageal Canc... Gastric Cancer | capecitabine docetaxel fluorouracil oxaliplatin radiation thera... therapeutic con... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer | NCT01498289 | Adenocarcinoma ... Esophageal Canc... Gastric Cancer | FOLFOX regimen docetaxel fluorouracil irinotecan hydr... leucovorin calc... oxaliplatin | 18 Years - 120 Years | SWOG Cancer Research Network | |
| Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery | NCT01705340 | Adenocarcinoma ... HER2-positive B... Male Breast Can... Recurrent Breas... Recurrent Esoph... Recurrent Gastr... Stage IIIC Brea... Stage IIIC Esop... Stage IIIC Gast... Stage IV Breast... Stage IV Esopha... Stage IV Gastri... | Akt inhibitor M... trastuzumab lapatinib ditos... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| 64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer | NCT01939275 | Adenocarcinoma ... Diffuse Adenoca... Intestinal Aden... Mixed Adenocarc... Recurrent Gastr... Stage IA Gastri... Stage IB Gastri... Stage IIA Gastr... Stage IIB Gastr... Stage IIIA Gast... Stage IIIB Gast... Stage IIIC Gast... Stage IV Gastri... | copper Cu 64-DO... positron emissi... laboratory biom... Computed Tomogr... | 18 Years - | City of Hope Medical Center | |
| Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer | NCT01212822 | Adenocarcinoma ... Adenocarcinoma ... Diffuse Adenoca... Intestinal Aden... Mixed Adenocarc... Squamous Cell C... Stage IA Esopha... Stage IA Gastri... Stage IB Esopha... Stage IB Gastri... Stage IIA Esoph... Stage IIA Gastr... Stage IIB Esoph... Stage IIB Gastr... Stage IIIA Esop... Stage IIIA Gast... Stage IIIB Esop... Stage IIIB Gast... Stage IIIC Esop... Stage IIIC Gast... | bevacizumab oxaliplatin leucovorin calc... fluorouracil therapeutic con... laboratory biom... | 18 Years - | Fox Chase Cancer Center | |
| Explorative Phase II Study of Perioperative Treatment in Patients With Adenocarcinoma of the Gastroesophageal Junction or Stomach | NCT01472029 | Adenocarcinoma ... Adenocarcinoma ... | 5-FU, leucovori... Post-operative ... | 18 Years - | AIO-Studien-gGmbH | |
| Symptom Control With or Without Docetaxel in Treating Patients With Relapsed Esophageal Cancer or Stomach Cancer | NCT00978549 | Adenocarcinoma ... Esophageal Canc... Gastric Cancer Nausea and Vomi... Pain | docetaxel steroid therapy questionnaire a... nausea and vomi... pain therapy quality-of-life... standard follow... radiation thera... | 18 Years - | National Cancer Institute (NCI) | |
| Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer | NCT00253370 | Adenocarcinoma ... Metastatic Gast... Advanced Unrese... | BAY 43-9006 docetaxel cisplatin | 18 Years - | National Cancer Institute (NCI) | |
| Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | NCT00084604 | Adenocarcinoma ... Diffuse Adenoca... Intestinal Aden... Mixed Adenocarc... Recurrent Gastr... Stage IIIA Gast... Stage IIIB Gast... Stage IIIC Gast... Stage IV Gastri... | irinotecan hydr... bevacizumab cisplatin computed tomogr... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer | NCT01178944 | Adenocarcinoma ... Esophageal Undi... Gastric Adenoca... Gastric Squamou... Recurrent Esoph... Recurrent Esoph... Recurrent Gastr... Stage IIIB Esop... Stage IIIB Esop... Stage IIIB Gast... Stage IIIC Esop... Stage IIIC Esop... Stage IIIC Gast... Stage IV Esopha... Stage IV Esopha... Stage IV Gastri... Undifferentiate... | Laboratory Biom... Oxaliplatin Pralatrexate | 18 Years - | Roswell Park Cancer Institute | |
| A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer | NCT00064259 | Adenocarcinoma ... Adenocarcinoma ... Diffuse Adenoca... Intestinal Aden... Mixed Adenocarc... Recurrent Esoph... Recurrent Gastr... Squamous Cell C... Stage III Esoph... Stage IIIA Gast... Stage IIIB Gast... Stage IIIC Gast... Stage IV Esopha... Stage IV Gastri... | oblimersen sodi... cisplatin fluorouracil | 19 Years - | National Cancer Institute (NCI) | |
| Lapatinib With Carboplatin and Paclitaxel in Esophagus and Gastroesophageal Junction (GEJ) | NCT01395537 | Adenocarcinoma ... Adenocarcinoma ... | Carboplatin AUC Paclitaxel lapatinib | 18 Years - | Case Comprehensive Cancer Center | |
| Induction FLOT With CROSS CRT for Esophageal Cancer | NCT04028167 | Adenocarcinoma ... Adenocarcinoma ... | Sequential FLOT... | 18 Years - 100 Years | University of Colorado, Denver | |
| Fluorouracil, Cisplatin, Leucovorin Calcium, and Cetuximab in Treating Patients With Adenocarcinoma of the Stomach or Gastroesophageal Junction | NCT01360086 | Adenocarcinoma ... Gastric Cancer | cetuximab cisplatin fluorouracil leucovorin calc... adjuvant therap... neoadjuvant the... quality-of-life... therapeutic con... | 18 Years - 75 Years | Federation Francophone de Cancerologie Digestive | |
| Study of Physical and Psychosocial Rehabilitation Needs of Patients After Diagnosis and Treatment of Upper Gastrointestinal Cancer or Gynecological Cancer | NCT01216813 | Adenocarcinoma ... Cervical Cancer Endometrial Can... Esophageal Canc... Fallopian Tube ... Gastric Cancer Ovarian Cancer Sarcoma Vaginal Cancer Vulvar Cancer | informational i... assessment of t... psychosocial as... | 18 Years - 120 Years | National Cancer Institute (NCI) | |
| 64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer | NCT01939275 | Adenocarcinoma ... Diffuse Adenoca... Intestinal Aden... Mixed Adenocarc... Recurrent Gastr... Stage IA Gastri... Stage IB Gastri... Stage IIA Gastr... Stage IIB Gastr... Stage IIIA Gast... Stage IIIB Gast... Stage IIIC Gast... Stage IV Gastri... | copper Cu 64-DO... positron emissi... laboratory biom... Computed Tomogr... | 18 Years - | City of Hope Medical Center | |
| A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer | NCT00064259 | Adenocarcinoma ... Adenocarcinoma ... Diffuse Adenoca... Intestinal Aden... Mixed Adenocarc... Recurrent Esoph... Recurrent Gastr... Squamous Cell C... Stage III Esoph... Stage IIIA Gast... Stage IIIB Gast... Stage IIIC Gast... Stage IV Esopha... Stage IV Gastri... | oblimersen sodi... cisplatin fluorouracil | 19 Years - | National Cancer Institute (NCI) | |
| Study of Blood and Tissue Samples From Patients With Stomach Cancer, Esophageal Cancer, or Gastroesophageal Junction Cancer | NCT00963092 | Adenocarcinoma ... Esophageal Canc... Gastric Cancer | DNA analysis RNA analysis microarray anal... protein analysi... cytology specim... laboratory biom... questionnaire a... | 16 Years - | National Cancer Institute (NCI) | |
| Regorafenib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction Who Have Completed Chemoradiation Therapy and Surgery | NCT02234180 | Adenocarcinoma ... Stage IIB Esoph... Stage IIIA Esop... Stage IIIB Esop... Stage IIIC Esop... | Placebo Regorafenib | 18 Years - | Academic and Community Cancer Research United | |
| FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma | NCT02037048 | Adenocarcinoma ... Adenocarcinoma ... Adenocarcinoma ... Stage IIIA Esop... Stage IIIB Esop... Stage IIIC Esop... | oxaliplatin leucovorin calc... fluorouracil therapeutic con... radiation thera... carboplatin paclitaxel | 18 Years - | Case Comprehensive Cancer Center | |
| A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab | NCT02013154 | Esophageal Neop... Adenocarcinoma ... Gastroesophagea... Squamous Cell C... Gastric Adenoca... | DKN-01 150 mg Paclitaxel Pembrolizumab DKN-01 300 mg | 18 Years - | Leap Therapeutics, Inc. | |
| Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer | NCT00253370 | Adenocarcinoma ... Metastatic Gast... Advanced Unrese... | BAY 43-9006 docetaxel cisplatin | 18 Years - | National Cancer Institute (NCI) | |
| Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction | NCT00891878 | Adenocarcinoma ... Esophageal Canc... | capecitabine sunitinib malat... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach | NCT01640782 | Adenocarcinoma ... Adenocarcinoma ... | Irinotecan, Leu... Leucovorin, 5-F... | 18 Years - 75 Years | Mario Negri Institute for Pharmacological Research | |
| Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery | NCT01612546 | Adenocarcinoma ... Adenocarcinoma ... Diffuse Adenoca... Intestinal Aden... Mixed Adenocarc... Recurrent Esoph... Recurrent Gastr... Squamous Cell C... Stage IIIB Esop... Stage IIIB Gast... Stage IIIC Esop... Stage IIIC Gast... Stage IV Esopha... Stage IV Gastri... | cyclodextrin-ba... Laboratory biom... Pharmacological... | 18 Years - | City of Hope Medical Center | |
| Symptom Control With or Without Docetaxel in Treating Patients With Relapsed Esophageal Cancer or Stomach Cancer | NCT00978549 | Adenocarcinoma ... Esophageal Canc... Gastric Cancer Nausea and Vomi... Pain | docetaxel steroid therapy questionnaire a... nausea and vomi... pain therapy quality-of-life... standard follow... radiation thera... | 18 Years - | National Cancer Institute (NCI) | |
| Validation of a Nutrition Screening Tool | NCT01851928 | Adenocarcinoma ... Cervical Cancer Endometrial Can... Esophageal Canc... Fallopian Tube ... Gastric Cancer Ovarian Cancer Sarcoma Vaginal Cancer Vulvar Cancer | 18 Years - 60 Years | Royal Marsden NHS Foundation Trust | ||
| Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer | NCT01123473 | Adenocarcinoma ... Gastric Cancer | capecitabine cisplatin epirubicin hydr... fluorouracil lapatinib ditos... | 18 Years - 75 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01] | NCT03329690 | Neoplasm, Gastr... | DS-8201a Physician's Cho... | 20 Years - | Daiichi Sankyo | |
| S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer | NCT01498289 | Adenocarcinoma ... Esophageal Canc... Gastric Cancer | FOLFOX regimen docetaxel fluorouracil irinotecan hydr... leucovorin calc... oxaliplatin | 18 Years - 120 Years | SWOG Cancer Research Network | |
| Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction | NCT00732745 | Adenocarcinoma ... Esophageal Canc... | docetaxel oxaliplatin vandetanib placebo | 18 Years - | Case Comprehensive Cancer Center | |
| Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery | NCT01107639 | Adenocarcinoma ... Esophageal Canc... | cetuximab cisplatin docetaxel adjuvant therap... neoadjuvant the... | 18 Years - 75 Years | Swiss Group for Clinical Cancer Research | |
| C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer | NCT02344810 | Adenocarcinoma ... Adenocarcinoma ... Diffuse Adenoca... Gastrointestina... Intestinal Aden... Mixed Adenocarc... Stage IIIA Esop... Stage IIIA Gast... Stage IIIB Esop... Stage IIIB Gast... Stage IIIC Esop... Stage IIIC Gast... Stage IV Esopha... Stage IV Gastri... | c-Met inhibitor... placebo oxaliplatin leucovorin calc... fluorouracil pharmacological... laboratory biom... | 18 Years - | Eastern Cooperative Oncology Group | |
| Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors | NCT04681248 | Esophageal Neop... Adenocarcinoma ... GastroEsophagea... Squamous Cell C... Gastric Adenoca... Endometrial Can... Uterine Cancer Ovarian Cancer Carcinosarcoma Gastric Cancer | DKN-01 | 18 Years - | Leap Therapeutics, Inc. | |
| Regorafenib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction Who Have Completed Chemoradiation Therapy and Surgery | NCT02234180 | Adenocarcinoma ... Stage IIB Esoph... Stage IIIA Esop... Stage IIIB Esop... Stage IIIC Esop... | Placebo Regorafenib | 18 Years - | Academic and Community Cancer Research United | |
| Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer | NCT00982592 | Adenocarcinoma ... Adenocarcinoma ... Recurrent Gastr... Stage IIIA Gast... Stage IIIB Gast... Stage IIIC Gast... Stage IV Gastri... | oxaliplatin leucovorin calc... fluorouracil placebo vismodegib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Study of Blood and Tissue Samples From Patients With Stomach Cancer, Esophageal Cancer, or Gastroesophageal Junction Cancer | NCT00963092 | Adenocarcinoma ... Esophageal Canc... Gastric Cancer | DNA analysis RNA analysis microarray anal... protein analysi... cytology specim... laboratory biom... questionnaire a... | 16 Years - | National Cancer Institute (NCI) | |
| A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery | NCT01183559 | Cancer of the E... Adenocarcinoma ... Cancer of the S... | Vandetanib 5 Fluorouracil ... Carboplatin Paclitaxel External Beam R... | 18 Years - | Fox Chase Cancer Center | |
| Study of Physical and Psychosocial Rehabilitation Needs of Patients After Diagnosis and Treatment of Upper Gastrointestinal Cancer or Gynecological Cancer | NCT01216813 | Adenocarcinoma ... Cervical Cancer Endometrial Can... Esophageal Canc... Fallopian Tube ... Gastric Cancer Ovarian Cancer Sarcoma Vaginal Cancer Vulvar Cancer | informational i... assessment of t... psychosocial as... | 18 Years - 120 Years | National Cancer Institute (NCI) | |
| Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer | NCT01212822 | Adenocarcinoma ... Adenocarcinoma ... Diffuse Adenoca... Intestinal Aden... Mixed Adenocarc... Squamous Cell C... Stage IA Esopha... Stage IA Gastri... Stage IB Esopha... Stage IB Gastri... Stage IIA Esoph... Stage IIA Gastr... Stage IIB Esoph... Stage IIB Gastr... Stage IIIA Esop... Stage IIIA Gast... Stage IIIB Esop... Stage IIIB Gast... Stage IIIC Esop... Stage IIIC Gast... | bevacizumab oxaliplatin leucovorin calc... fluorouracil therapeutic con... laboratory biom... | 18 Years - | Fox Chase Cancer Center | |
| Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer | NCT00607594 | Adenocarcinoma ... Adenocarcinoma ... Recurrent Gastr... Stage III Gastr... Stage III Esoph... Stage IV Esopha... Stage IV Gastri... | saracatinib | 18 Years - | National Cancer Institute (NCI) | |
| Explorative Phase II Study of Perioperative Treatment in Patients With Adenocarcinoma of the Gastroesophageal Junction or Stomach | NCT01472029 | Adenocarcinoma ... Adenocarcinoma ... | 5-FU, leucovori... Post-operative ... | 18 Years - | AIO-Studien-gGmbH | |
| Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery | NCT01705340 | Adenocarcinoma ... HER2-positive B... Male Breast Can... Recurrent Breas... Recurrent Esoph... Recurrent Gastr... Stage IIIC Brea... Stage IIIC Esop... Stage IIIC Gast... Stage IV Breast... Stage IV Esopha... Stage IV Gastri... | Akt inhibitor M... trastuzumab lapatinib ditos... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery | NCT00991952 | Adenocarcinoma ... Diffuse Adenoca... Intestinal Aden... Mixed Adenocarc... Recurrent Gastr... Stage IIIA Gast... Stage IIIB Gast... Stage IIIC Gast... Stage IV Gastri... | alvocidib irinotecan hydr... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Study of Guanábana Leaves for The Treatment of Patients With Gastric, Gastroesophageal Junction, Pancreatic and Colorectal Adenocarcinomas; Hepatocellular Carcinoma, and Low Grade Lymphomas | NCT04773769 | Gastric Adenoca... Adenocarcinoma ... Hepatocellular ... Pancreatic Aden... Low Grade Lymph... Colorectal Aden... | Tea Made of Gra... | 18 Years - | Auxilio Mutuo Cancer Center | |
| Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | NCT00084604 | Adenocarcinoma ... Diffuse Adenoca... Intestinal Aden... Mixed Adenocarc... Recurrent Gastr... Stage IIIA Gast... Stage IIIB Gast... Stage IIIC Gast... Stage IV Gastri... | irinotecan hydr... bevacizumab cisplatin computed tomogr... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01] | NCT03329690 | Neoplasm, Gastr... | DS-8201a Physician's Cho... | 20 Years - | Daiichi Sankyo | |
| Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction | NCT00757172 | Adenocarcinoma ... Esophageal Canc... | panitumumab cisplatin docetaxel neoadjuvant the... therapeutic con... radiation thera... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer | NCT00045526 | Adenocarcinoma ... Adenocarcinoma ... Recurrent Esoph... Squamous Cell C... Stage III Esoph... Stage IV Esopha... | erlotinib hydro... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab | NCT02013154 | Esophageal Neop... Adenocarcinoma ... Gastroesophagea... Squamous Cell C... Gastric Adenoca... | DKN-01 150 mg Paclitaxel Pembrolizumab DKN-01 300 mg | 18 Years - | Leap Therapeutics, Inc. | |
| Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer | NCT01212822 | Adenocarcinoma ... Adenocarcinoma ... Diffuse Adenoca... Intestinal Aden... Mixed Adenocarc... Squamous Cell C... Stage IA Esopha... Stage IA Gastri... Stage IB Esopha... Stage IB Gastri... Stage IIA Esoph... Stage IIA Gastr... Stage IIB Esoph... Stage IIB Gastr... Stage IIIA Esop... Stage IIIA Gast... Stage IIIB Esop... Stage IIIB Gast... Stage IIIC Esop... Stage IIIC Gast... | bevacizumab oxaliplatin leucovorin calc... fluorouracil therapeutic con... laboratory biom... | 18 Years - | Fox Chase Cancer Center | |
| Efficacy and Safety Study of the Combined Modality Therapy in Adenocarcinoma of the Esophago-gastric Junction | NCT01523015 | Adenocarcinoma ... | preoperative ch... Surgical resect... | 18 Years - | Medical University of Lublin | |
| Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach | NCT00061932 | Adenocarcinoma ... Diffuse Adenoca... Intestinal Aden... Mixed Adenocarc... Recurrent Gastr... Stage IIIB Gast... Stage IIIC Gast... Stage IV Gastri... | bortezomib irinotecan | 18 Years - | National Cancer Institute (NCI) | |
| Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer | NCT01307956 | Adenocarcinoma ... Esophageal Aden... Stage IIA Esoph... Stage IIB Esoph... | Fluorouracil Laboratory Biom... Leucovorin Calc... Oxaliplatin Panitumumab Pharmacological... Radiation Thera... Therapeutic Con... | 19 Years - | University of Nebraska | |
| Perioperative Chemo and Pembrolizumab in Gastric Cancer | NCT02918162 | Gastric Cancer Adenocarcinoma ... | Pembrolizumab Standard of car... | 18 Years - | Columbia University | |
| A Survivorship Care Plan for Gynaecological Cancer Patients | NCT01582906 | Adenocarcinoma ... Cervical Cancer Endometrial Can... Esophageal Canc... Fallopian Tube ... Gastric Cancer Ovarian Cancer Sarcoma Vaginal Cancer Vulvar Cancer | 18 Years - 60 Years | Royal Marsden NHS Foundation Trust | ||
| Lapatinib With Carboplatin and Paclitaxel in Esophagus and Gastroesophageal Junction (GEJ) | NCT01395537 | Adenocarcinoma ... Adenocarcinoma ... | Carboplatin AUC Paclitaxel lapatinib | 18 Years - | Case Comprehensive Cancer Center | |
| Induction FLOT With CROSS CRT for Esophageal Cancer | NCT04028167 | Adenocarcinoma ... Adenocarcinoma ... | Sequential FLOT... | 18 Years - 100 Years | University of Colorado, Denver | |
| Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer | NCT01260701 | Adenocarcinoma ... Diffuse Gastric... Gastric Intesti... Gastric Mixed A... Recurrent Gastr... | Akt Inhibitor M... | 18 Years - | National Cancer Institute (NCI) | |
| Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery | NCT01107639 | Adenocarcinoma ... Esophageal Canc... | cetuximab cisplatin docetaxel adjuvant therap... neoadjuvant the... | 18 Years - 75 Years | Swiss Group for Clinical Cancer Research | |
| Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer | NCT01260701 | Adenocarcinoma ... Diffuse Gastric... Gastric Intesti... Gastric Mixed A... Recurrent Gastr... | Akt Inhibitor M... | 18 Years - | National Cancer Institute (NCI) | |
| Induction FLOT With CROSS CRT for Esophageal Cancer | NCT04028167 | Adenocarcinoma ... Adenocarcinoma ... | Sequential FLOT... | 18 Years - 100 Years | University of Colorado, Denver | |
| Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer | NCT01178944 | Adenocarcinoma ... Esophageal Undi... Gastric Adenoca... Gastric Squamou... Recurrent Esoph... Recurrent Esoph... Recurrent Gastr... Stage IIIB Esop... Stage IIIB Esop... Stage IIIB Gast... Stage IIIC Esop... Stage IIIC Esop... Stage IIIC Gast... Stage IV Esopha... Stage IV Esopha... Stage IV Gastri... Undifferentiate... | Laboratory Biom... Oxaliplatin Pralatrexate | 18 Years - | Roswell Park Cancer Institute | |
| Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery | NCT01705340 | Adenocarcinoma ... HER2-positive B... Male Breast Can... Recurrent Breas... Recurrent Esoph... Recurrent Gastr... Stage IIIC Brea... Stage IIIC Esop... Stage IIIC Gast... Stage IV Breast... Stage IV Esopha... Stage IV Gastri... | Akt inhibitor M... trastuzumab lapatinib ditos... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH | NCT01855854 | Adenocarcinoma ... Esophageal Carc... | Icotinib | 18 Years - 75 Years | Betta Pharmaceuticals Co., Ltd. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
